Intervention

Respimat

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 13 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials13

Recruiting0

Common conditions3

Lead sponsors shown3

Clinical trials

13 shown

Re-usable Respimat® Soft MistTM Inhaler StudyNCT04011735 · 2019-09-30

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine ChallengeNCT02622243 · 2015-11-01

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD PatientsNCT01533922 · 2012-03-01

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary DiseaseNCT01559116 · 2012-03-01

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.NCT01533935 · 2012-02-01

Japan Long-term Safety for Tiotropium Plus OlodaterolNCT01536262 · 2012-02-01

Olodaterol Bridging Study in AsthmaNCT01428622 · 2011-10-01

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)NCT01431287 · 2011-09-01

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)NCT01431274 · 2011-09-01

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD PatientsNCT02331940 · 2010-03-01

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)NCT01040403 · 2010-01-01

Tiotropium / Respimat One Year Study in COPD.NCT00387088 · 2006-09-01

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT02175342 · 1998-03-01

Common conditions

Pulmonary Disease, Chronic Obstructive10 Asthma2 Chronic Obstructive Pulmonary Disease1

Leading sponsors

Boehringer Ingelheim 11 University of Crete 1 University of Saskatchewan 1

Trial status mix

COMPLETED12

WITHDRAWN1

Phase mix

PHASE37

PHASE23

NA1

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.